)
Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
not losing weight with semaglutide Woman Loses 82lbs on As Alternative to Bariatric Surgery Product Type_Capsules Size:240 CT Women's Nutritional Support for
Women's Nutritional Support for GLP-1 Users
Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
Product Type_Capsules
Size:240 CT
Licensed 503A compounding pharmacies must meet rigorous USP standards for sterility testing, contamination prevention, and ingredient sourcing verification
US$ 29.03
US$ 24.12
US$ 26.82
US$ 28.69
.jpg)
